Replies to post #33594 on MultiCell Technologies Inc (MCET)

[ospreyeye]

MCET: "Current approaches for treatment of hepatocellular carcinoma are of limited efficacy. MCT-485, possessing both oncolytic and immune activating properties, could be superior to doxorubicin, cisplatin and other currently marketed therapies by providing a more robust activation of immunity, and a more global and longer lasting anti-tumor effect."